In Greek mythology, a Chimera is a creature of change, a being possessing the forms of lion, goat and dragon. But unlike the mythical creature, a new approach to fighting cancer cells throughout the body is very real and has arrived at The University of New Mexico Comprehensive Cancer Center.
The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any malignant glioma in children or adults.
Research by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published today in the journal Cellular & Molecular Immunology.
Bolstered by $6.3 million raised in donations, the Rutgers Board of Governors today approved the establishment of the William Hait Endowed Directorship at Rutgers Cancer Institute. Moving forward, the director of Rutgers Cancer Institute will be known as the William Hait Director.
20221027104337.jpg&width=400&height=400)
Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers.
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.
The Bristol-Myers Squibb Children’s Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and Rutgers Cancer Institute recently dedicated the new Pediatric Bone Marrow Transplantation and Cellular Therapy Program recognizing the many donors who supported the program.
New recommendations on the optimal use of radiation therapy for HPV-associated OPSCC are based on evidence from multiple clinical trials and aim to maintain good outcomes and reduce acute and late effects.
The Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory council to identify needs and opportunities for data science development and integration across MD Anderson, advancing work that will yield significant benefits for patients and families.
Fred Hutch Cancer Center announced eight recipients of the national Dr. Eddie Méndez Scholar Award, which recognizes which recognizes outstanding early-career scientists from underrepresented backgrounds who are studying cancer, infectious diseases and basic sciences.
NCCN Guidelines for Patients earn Hermes Award for electronic media and Communicator Award for medical print content. NCCN Patient Webinars earn Digital Health Award and Viddy Award for outstanding achievement in video and digital production.
Immunotherapy, a type of cancer treatment that uses a person’s own immune system to attack cancer cells, is continuing to transform cancer treatment and care.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The UNM Comprehensive Cancer Center is partnering with Northern Arizona University, New Mexico State University and the Burrell College of Osteopathic Medicine, which is located on NMSU’s campus in Las Cruces, to connect emerging cancer disparities researchers with mentors to continue developing these scholars.
The University of Texas MD Anderson Cancer Center and Sibylla Biotech today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.
Researchers at Brigham and Women’s Hospital and Dana-Farber Cancer Institute found significant uptake and scalability in phone-based “PATH” intervention to improve psychological well-being in blood cancer patients, according to new study in JNCCN.
Leptomeningeal disease is a rare but lethal complication faced by late-stage melanoma patients. It occurs when cancer cells spread to the membranes covering the brain and spinal cord, or the leptomeninges. This condition, which affects 5% to 8% of melanoma patients, often leads to rapid deterioration and is notoriously resistant to therapies. However, a new Moffitt Cancer Center study, published today in Cell Reports Medicine, uncovers the mechanisms that drive this drug resistance, offering new avenues for potential treatments.
New study shows UC Davis total-body advanced PET scanner EXPLORER can visualize dual blood supply in lungs and effectively evaluate lung cancer and track treatment progress.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right